Learn how Slope’s eClinical Supply Chain Management platform provides robust technology to the clinical trial space, covering all areas of supply management without losing sight of the chain of custody.

Learn how Slope’s eClinical Supply Chain Management platform provides robust technology to the clinical trial space, covering all areas of supply management without losing sight of the chain of custody.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

[Sponsored] Slope’s Hope Meely on the importance of a fully enabled clinical supply platform

After a complicated 2022, the new year offers a course correction for the obesity market. We'll hear from Fierce's Fraiser Kansteiner and Querida Anderson on the numerous opportunities ahead in the obesity market. 

Also on the show, Fierce's Kevin Dunleavy and Eric Sagonowsky reflect on the the 37 new drugs approved in 2022. Plus, this week's headlines. 

To learn more about topics in this episode:
2023 forecast: With Novo's Wegovy on a supply rebound, 2023 offers course correction and obesity showdown with Lilly
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy
2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37
Time to shine, biosims: Amgen's Amjevita readies long-awaited assault on AbbVie's Humira
Amgen's Humira biosimilar Amjevita hits the market with 2 different list prices
In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better
Philips cuts another 6,000 jobs as CPAP recall, supply chain snags send 2022 sales down 3%
Researchers predict Alzheimer's progression 3.5 years early with unique blood test

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

After a complicated 2022, the new year offers a course correction for the obesity market. We'll hear from Fierce's Fraiser Kansteiner and Querida Anderson on the numerous opportunities ahead in the obesity market. 
Also on the show, Fierce's Kevin Dunleavy and Eric Sagonowsky reflect on the the 37 new drugs approved in 2022. Plus, this week's headlines. 
To learn more about topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/pharma/2023-forecast-novos-wegovy-supply-rebound-2023-offers-course-correction-ahead-obesity">2023 forecast: With Novo's Wegovy on a supply rebound, 2023 offers course correction and obesity showdown with Lilly</a></li>
<li><a href="https://www.fiercepharma.com/pharma/novo-nordisk-s-semaglutide-snags-hotly-anticipated-greenlight-obesity">Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light</a></li>
<li><a href="https://www.fiercepharma.com/pharma/lillys-tirzepatide-slides-fda-fast-track-lane-obesity-turning-heat-novo-nordisks-wegovy">Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy</a></li>
<li><a href="https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come">2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37</a></li>
<li><a href="https://www.fiercepharma.com/pharma/amgens-amjevita-enters-ring-first-player-booming-humira-biosimilar-market">Time to shine, biosims: Amgen's Amjevita readies long-awaited assault on AbbVie's Humira</a></li>
<li><a href="https://www.fiercepharma.com/pharma/amgens-humira-biosimilar-amjevita-hits-market-two-different-list-prices">Amgen's Humira biosimilar Amjevita hits the market with 2 different list prices</a></li>
<li><a href="https://www.fiercepharma.com/pharma/mysterious-approval-pfizer-quietly-wins-ibrance-breast-cancer-expansion-after-fda-requested">In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-sees-covid-19-vaccine-sales-falling-64-2023-paxlovid-declining-58">Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/philips-cuts-another-6000-jobs-cpap-recall-supply-chain-snags-send-2022-sales-down-3">Philips cuts another 6,000 jobs as CPAP recall, supply chain snags send 2022 sales down 3%</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/researchers-predict-alzheimers-progression-35-years-early-unique-blood-test">Researchers predict Alzheimer's progression 3.5 years early with unique blood test</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

February 3rd, 2023

Just last year, congress passed the Inflation Reduction Act. The law contains several drug pricing measures hated by the pharmaceutical industry, including restrictions to price increases and Medicare negotiations. Eric Sagnowsky talked with Stacie Dusetzina, a professor at Vanderbilt University's Department of Health Policy, about what we can expect. 

Also on the show, Fierce's Analee Armstrong and Gabrielle Mason reflect on the biotech industry last year and our expectation for 2023—plus, this week's headlines. 

To learn more about topics in this episode:
2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'
2023 forecast: Biotech plummeted from 'the highest of highs' in 2022. Will the sun shine again next year?
Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M
Fierce Biotech Layoff Tracker: Layoffs strike 119 companies in 2022
Theranos' Elizabeth Holmes labeled a 'flight risk' as she asks to delay prison sentence during appeal
Eli Lilly shut out of Alzheimer's fast lane with FDA rejection for donanemab
Health group lambasts CBS ‘60 Minutes’ segment for overt promotion of Novo Nordisk’s obesity med Wegovy
Eli Lilly to pour $450M more into diabetes drug plant in North Carolina, add 100 jobs
Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff and seek buyers for assets

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Just last year, congress passed the Inflation Reduction Act. The law contains several drug pricing measures hated by the pharmaceutical industry, including restrictions to price increases and Medicare negotiations. Eric Sagnowsky talked with Stacie Dusetzina, a professor at Vanderbilt University's Department of Health Policy, about what we can expect. 
Also on the show, Fierce's Analee Armstrong and Gabrielle Mason reflect on the biotech industry last year and our expectation for 2023—plus, this week's headlines. 
To learn more about topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/pharma/whats-next-drug-pricing-2023">2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/2023-forecast-after-year-torrential-reductions-biotech-industry-yearns-brighter-days-are">2023 forecast: Biotech plummeted from 'the highest of highs' in 2022. Will the sun shine again next year?</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker">Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2022">Fierce Biotech Layoff Tracker: Layoffs strike 119 companies in 2022</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/theranos-elizabeth-holmes-labeled-flight-risk-she-asks-delay-prison-sentence-during-appeal">Theranos' Elizabeth Holmes labeled a 'flight risk' as she asks to delay prison sentence during appeal</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/eli-lilly-shut-out-alzheimers-fast-lane-complete-response-letter-donanemab">Eli Lilly shut out of Alzheimer's fast lane with FDA rejection for donanemab</a></li>
<li><a href="https://www.fiercepharma.com/marketing/health-group-lambasts-novo-nordisk-60-minutes-paid-news-program-weight-loss-med-wegovy">Health group lambasts CBS ‘60 Minutes’ segment for overt promotion of Novo Nordisk’s obesity med Wegovy</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/eli-lilly-will-our-450m-more-diabetes-drug-plant-north-carolina">Eli Lilly to pour $450M more into diabetes drug plant in North Carolina, add 100 jobs</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/frosty-funding-forecast-forces-finch-stop-phase-3-trial-lay-95-staff-and-seek-buyers-assets">Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff and seek buyers for assets</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

January 27th, 2023

Fierce’s JPM Week event was packed full of informative panels, executive interviews and fireside chats. So for today’s episode, we’ve pulled out a couple of snippets to take you inside the gathering.

First up, listen in on Fraiser Kansteiner’s lively panel discussion on how companies will keep their bottom lines strong while navigating the drug pricing policies that the Biden administration rolled out just last year. You will also hear from Zoey Becker’s interview with Bayer’s Christine Roth. As head of the oncology strategic business unit, Roth talks about the plans to establish Bayer as a strong competitor in the cancer space.

To learn more about topics in this episode:
2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'
To bolster IRA, lawmaker calls for new action to scrutinize cancer drug launch prices
Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report
JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each
Look out, Pfizer. With new approval, Bayer's Nubeqa is set to challenge Xtandi's prostate cancer crown
Bayer's blockbuster hopeful Nubeqa debuts in later-stage prostate cancer in UK under early access program
Bayer poaches GlaxoSmithKline exec to lead expanding oncology business—including a blockbuster hopeful
Fierce JPM Week

The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Fierce’s JPM Week event was packed full of informative panels, executive interviews and fireside chats. So for today’s episode, we’ve pulled out a couple of snippets to take you inside the gathering.
First up, listen in on Fraiser Kansteiner’s lively panel discussion on how companies will keep their bottom lines strong while navigating the drug pricing policies that the Biden administration rolled out just last year. You will also hear from Zoey Becker’s interview with Bayer’s Christine Roth. As head of the oncology strategic business unit, Roth talks about the plans to establish Bayer as a strong competitor in the cancer space.
To learn more about topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/pharma/whats-next-drug-pricing-2023">2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'</a></li>
<li><a href="https://www.fiercepharma.com/pharma/fix-ira-loophole-lawmaker-calls-new-action-scrutinize-cancer-drugs-launch-prices">To bolster IRA, lawmaker calls for new action to scrutinize cancer drug launch prices</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-gsk-abbvie-and-many-more-ring-new-year-price-hikes-report">Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report</a></li>
<li><a href="https://www.fiercepharma.com/pharma/jpm23-bayer-sees-3b-potential-each-kerendia-nubeqa-13b-overall-growth-drivers">JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each</a></li>
<li><a href="https://www.fiercepharma.com/pharma/look-out-pfizer-bayers-nubeqa-coming-xtandis-prostate-cancer-crown">Look out, Pfizer. With new approval, Bayer's Nubeqa is set to challenge Xtandi's prostate cancer crown</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bayers-blockbuster-hopeful-nubeqa-shifts-later-stage-prostate-cancer-under-uk-early-access">Bayer's blockbuster hopeful Nubeqa debuts in later-stage prostate cancer in UK under early access program</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bayer-poaches-glaxosmithkline-exec-to-lead-expanding-oncology-business">Bayer poaches GlaxoSmithKline exec to lead expanding oncology business—including a blockbuster hopeful</a></li>
<li><a href="https://www.fiercejpmweek.com/">Fierce JPM Week</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

[Sponsored] Slope’s Hope Meely on the importance of a fully enabled clinical supply platform

In 1 playlist(s)

The Top Line

Social links

Recent clips